Phaseline

Companies › Monte Rosa Therapeutics

Monte Rosa Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Other, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MRT-2359
GSPT1 molecular glue degrader
GSPT1Phase 2Castration-Resistant Prostate Cancer (CRPC); NSCLCDec 2026
MRT-8102–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07119125MRT-8102Phase 1Healthy VolunteersOtherJul 2026
NCT05546268MRT-2359Phase 1NSCLCOncologyDec 2026
NCT07745361MRT-2359Phase 2Castration-Resistant Prostate Cancer (CRPC)OncologyOct 2027

From the company's SEC filings

Cash and short-term investments of $578m on 2026-09-30; operating cash outflow about $164m a year; runway about 42 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GSPT1 (1)

Companies with the same targets

–

Companies built like this

Haihe Biopharma J-Pharma Ranok Therapeutics (Hangzhou) Kymera Therapeutics C4 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.